NCT07160868 Obstructive Sleep Apnoea and Difficult Asthma (OSADA)
| NCT ID | NCT07160868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. James's Hospital, Ireland |
| Condition | Asthma (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-05-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-09-01 with a primary completion date of 2026-05-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The OSADA (Obstructive Sleep Apnoea in Difficult Asthma) trial is an open-label, randomized control trial investigating the impact of diagnosing and treating obstructive sleep apnoea (OSA) on a asthma control in patients with difficult-to-control asthma. Participants will undergo home-based sleep studies to assess for OSA and are then allocated to one of three arms: 1) Patients with OSA treated with CPAP (intervention group), 2) Patients with OSA not treated for OSA (control group) and 3) Patients without OSA (reference group). The primary objective is to evaluate whether treating OSA improves asthma control, symptom burden, and quality of life compared to untreated OSA and to patients without OSA. Secondary outcomes include exacerbation rates, sleep quality, and healthcare utilization. This trial aims to clarify the contribution of OSA to poor asthma control and the potential benefits of integrated sleep and respiratory care in this complex population.
Eligibility Criteria
Inclusion Criteria: * Patients must have a clinical diagnosis of asthma with supportive objective diagnostics including but not limited to, variable airflow obstruction, bronchial-hyper responsiveness and demonstrable eosinophilic inflammation via fractional exhaled nitric oxide or peripheral eosinophilia * Patients receiving step 4 or step 5 of 'The Global Initiative for Asthma' (GINA) treatment guidelines will be selected * Between the ages of 18 to 90 years of age Exclusion Criteria: * Patients with previous sleep study investigations * Excessive daytime sleepiness; ESS \>17 * Previous diagnosis of a sleep disorder * Resting hypoxaemia or need for long-term oxygen therapy * Inability to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07160868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Asthma (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07160868 currently recruiting?
Yes, NCT07160868 is actively recruiting participants. Contact the research team at laurampiggott@gmail.com for enrollment information.
Where is the NCT07160868 trial being conducted?
This trial is being conducted at Dublin, Ireland.
Who is sponsoring the NCT07160868 clinical trial?
NCT07160868 is sponsored by St. James's Hospital, Ireland. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.